Form 4: Alkermes Director Shane Cooke Reports Stock Option and Restricted Stock Unit Award
SEC Form 4
Director Shane Cooke reports acquisition of stock options and restricted stock units in Alkermes plc.
Summary
- On May 31, 2024, Shane Cooke, a director of Alkermes plc, reported the acquisition of derivative securities.
- These acquisitions include 17,492 non-qualified stock options with an exercise price of $23.40, vesting fully on May 31, 2025, and expiring on May 31, 2034.
- Cooke also acquired 8,013 restricted stock units, vesting fully on May 31, 2025.
- The filing also includes a power of attorney, effective February 6, 2024, granting certain individuals the authority to act on Cooke's behalf in matters related to SEC filings.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock option and RSU grants. While insider ownership can be a positive signal, this is part of a compensation package and doesn't necessarily indicate strong positive sentiment from the director.
Positives
- The acquisition of stock options and restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedules of the stock options and restricted stock units indicate a multi-year horizon.
Industry Context
This filing is a routine disclosure related to executive compensation and insider transactions, common in the pharmaceutical industry where equity-based compensation is frequently used.
Comparison to Industry Standards
- Equity compensation is a standard practice in the pharmaceutical industry to align the interests of executives with those of shareholders.
- Companies like Amgen, Biogen, and Vertex Pharmaceuticals also utilize stock options and restricted stock units as part of their executive compensation packages.
- The vesting schedules and exercise prices are generally comparable to industry norms for similar roles and company sizes.
Stakeholder Impact
- The granting of stock options and restricted stock units can incentivize management to improve company performance, potentially benefiting shareholders.
- Employees may be indirectly impacted through the overall performance of the company.
Key Dates
| Date | Description |
|---|---|
| February 6, 2024 | Effective date of the Power of Attorney. |
| May 31, 2024 | Date of the reported transaction (acquisition of stock options and restricted stock units). |
| May 31, 2025 | Vesting date for the acquired restricted stock units and stock options. |
| May 31, 2034 | Expiration date for the acquired stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.